Fluicell AB (5J90) Price & Analysis

3 Followers

5J90 Stock Chart & Stats

€1.29

Market closed

€1.29

Day’s Range― - ―

52-Week Range€0.72 - €5.22

Previous CloseN/A

VolumeN/A

Average Volume (3M)94.00

Market Cap

€4.35M

Enterprise Value€13.95

Total Cash (Recent Filing)€1.30M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta5.91

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding1,373,703

10 Day Avg. Volume182

30 Day Avg. Volume94

Financial Highlights & Ratios

PEG Ratio1.01

Price to Book (P/B)74.56

Price to Sales (P/S)135.42

P/FCF Ratio-59.71

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€6.35M

Bulls Say, Bears Say

Bulls Say

Strong Revenue ReboundThe sharp TTM revenue rebound indicates improving customer adoption and commercial traction. Sustained growth would expand the base over which Fluicell can spread its operating costs and develop a more scalable research-tools business.

Positive Gross ProfitPositive gross profit suggests Fluicell's products generate economic value before operating expenses. If maintained, this provides a foundation for future margin improvement as sales scale and the company gains greater efficiency in its early-stage cost structure.

Debt-Free Balance SheetZero debt reduces refinancing pressure, interest obligations, and balance-sheet risk while Fluicell develops its platform. Positive equity also provides a stronger financial base than a highly leveraged structure, although funding needs remain.

Bears Say

Persistent UnprofitabilityPersistent operating and net losses show that current revenue is not yet sufficient to support the full cost base. Without sustained scale or cost reductions, Fluicell may remain dependent on external funding and face pressure to improve execution.

Continued Cash BurnNegative operating and free cash flow limit the company's ability to finance development and commercial expansion internally. Ongoing cash burn increases the likelihood of future capital needs, which could constrain strategy or dilute existing shareholders.

Volatile Early-Stage Cost StructureLarge swings in gross profitability indicate that the business has not yet achieved a stable, scaled operating model. This volatility makes future results less predictable and suggests that product mix, volume, or project timing can materially affect financial performance.

5J90 FAQ

What was Fluicell AB’s price range in the past 12 months?

Fluicell AB lowest stock price was €0.72 and its highest was €5.22 in the past 12 months.

What is Fluicell AB’s market cap?

Fluicell AB’s market cap is €4.35M.

When is Fluicell AB’s upcoming earnings report date?

Fluicell AB’s upcoming earnings report date is Nov 13, 2026 which is in 77 days.

How were Fluicell AB’s earnings last quarter?

Currently, no data Available

Is Fluicell AB overvalued?

According to Wall Street analysts Fluicell AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fluicell AB pay dividends?

Fluicell AB does not currently pay dividends.

What is Fluicell AB’s EPS estimate?

Fluicell AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fluicell AB have?

Fluicell AB has 1,373,703 shares outstanding.

What happened to Fluicell AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Fluicell AB?

Currently, no hedge funds are holding shares in DE:5J90

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fluicell AB

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.